IRA Labs

IRA Labs is a French biotechnology company focused on the discovery and development of first-in-class small molecule antagonists targeting innate immune receptors, specifically Toll-like receptors (TLR7, TLR8, and TLR9). The company's proprietary platform leverages deep expertise in innate immunity to design highly selective inhibitors aimed at treating chronic inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis. By modulating the overactivation of the innate immune system, IRA Labs seeks to provide transformative therapies for patients with high unmet medical needs. The company is currently in the pre-clinical stage, advancing its lead candidates toward IND-enabling studies. Founded as a spin-off from the CNRS and Université de Paris, IRA Labs combines academic excellence with drug discovery expertise to address the root causes of interferon-mediated pathologies.